IceCure's Innovative ProSense® Cryoablation System Promotes Advanced Breast Cancer Care

IceCure Medical Illuminates the Future of Breast Cancer Care with ProSense® at TME Fall Summit

IceCure Medical Ltd., a pioneer in minimally invasive cryoablation technology, has made significant waves in the arena of breast cancer treatment with its cutting-edge product, ProSense®. Recently featured at the TME (Take the Lead in Breast Cancer Care) Fall Summit 2025, which occurred from September 26-27 in New Orleans, this innovative solution aims to provide an alternative to traditional surgical tumor removal methods.

The TME Fall Summit attracted over 40 distinguished Key Opinion Leaders (KOLs) from across the United States, including esteemed breast surgeons, medical oncologists, and interventional radiologists. These professionals gathered to explore advancements in multidisciplinary care for patients facing high-risk and newly diagnosed breast cancer. Notably, the event spotlighted the evolving conversation around de-escalating treatment for early and high-risk breast cancer patients, emphasizing the increasing relevance of minimally invasive options like cryoablation.

A groundbreaking moment for IceCure came mere days after the summit. On October 3, 2025, the U.S. Food and Drug Administration (FDA) granted marketing authorization for ProSense® to treat local breast cancer in patients aged 70 and above with biologically low-risk tumors not exceeding 1.5 cm. This approval is particularly crucial for patients who are unfit for surgical alternatives. Eyal Shamir, CEO of IceCure, expressed excitement about the high level of interest generated during the roundtable, highlighting the momentum surrounding less invasive strategies in breast cancer treatment. Shamir believes that this interest will lead to greater clinical adoption of ProSense® following its recent FDA clearance.

The spotlight on cryoablation was exemplified during a session moderated by Dr. Richard Fine, an influential researcher associated with IceCure's ICE3 trial, which stands as the largest study on cryoablation in the U.S. Dr. Fine is also the notable recipient of the 2024 American Society of Breast Surgeons' Scientific Impact Award, recognizing his exceptional presentation of results from the ICE3 trial.

IceCure took this opportunity not just to discuss its recent achievements, but also to showcase the ProSense® system's capabilities. ProSense® is the first and only FDA-authorized medical device designed for the localized treatment of low-risk breast cancer in older women. This revolutionary system provides guidance for the precision destruction of tumors through a minimally invasive method that utilizes liquid nitrogen to create lethal freezing zones.

The advantages offered by ProSense® are substantial. Not only does it accelerate patient recovery times and minimize pain, but it also reduces the overall risks associated with surgery and postoperative complications. The transportable design of the ProSense® device facilitates quick, convenient procedures in outpatient settings, heralding a new era of care for patients with breast tumors.

At its core, IceCure Medical is dedicated to enhancing treatment options and outcomes in various types of tumors, including those found in the breast, kidney, lung, and liver. With its commitment to spearheading minimally invasive treatments, IceCure continues to establish itself as a leader in the field of cryoablation therapy.

In conclusion, the TME Fall Summit underscored the great potential that ProSense® holds for reshaping breast cancer treatment paradigms. As interest among healthcare professionals grows, IceCure Medical is poised to make significant strides in how breast cancer care is administered, particularly for those patients who are seeking less invasive alternatives to surgery. As this narrative unfolds, the medical community and patients alike await the positive impacts that ProSense® can deliver in this critical area of healthcare.